Brought to you by 
Swedish Orphan buys Dova for $915mm
31 Aug 2020
Executive Summary
Swedish Orphan Biovitrum AB (Sobi) signed a definitive agreement to acquire Dova Pharmaceuticals Inc., a public three-year-old hematology drug company. The total potential value of the deal could hit $915mm, including $27.50 per Dova share in cash (a 55% premium to the 10-day pre-announcement market average) and contingent value rights entitling Dova shareholders to $1.50 per share.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Swedish Orphan buys Dova for $915mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice